A qualitative study of using nicotine products for smoking cessation after discharge from residential drug and alcohol treatment in Australia.
alcohol and other drugs
nicotine replacement therapy
smoking cessation
vaping
withdrawal treatment
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
23 Apr 2024
23 Apr 2024
Historique:
revised:
08
03
2024
received:
06
03
2023
accepted:
03
04
2024
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
23
4
2024
Statut:
aheadofprint
Résumé
Tobacco smoking is highly prevalent among alcohol and other drugs (AOD) service clients and, despite interest in quitting, abstinence is rarely sustained. Nicotine products may assist after discharge from residential treatment services, but little is known about client receptivity to them. This study examined AOD withdrawal service clients' experiences of two types of nicotine products for smoking cessation post-discharge, combination nicotine replacement therapy (cNRT) and nicotine vaping products (NVP). We held semi-structured telephone interviews with 31 Australian AOD service clients in a clinical trial of a 12-week smoking cessation intervention using Quitline support plus cNRT or NVP delivered post-discharge from a smoke-free residential service. We asked about health and social factors, nicotine cravings, Quitline experience, and barriers and facilitators to cNRT or NVP, then thematically analysed data. cNRT and NVP were described by participants as feasible and acceptable for smoking cessation. For most participants, cost limited cNRT access post study, as did difficulty navigating NVP prescription access. Quitline support was valued, but not consistently used, with participants noting low assistance with NVP-facilitated cessation. Participants considered both cessation methods acceptable and socially supported, and sought information on decreasing nicotine use via NVP. AOD service clients highly valued receiving cNRT or NVP with behavioural support for smoking reduction or abstinence. Both interventions were acceptable to service clients. Findings suggest a potential need to examine both whether NVP use should be permitted in this context, and guidance on the individual suitability of cNRT or NVP.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Health and Medical Research Council
ID : GNT1160245
Organisme : National Health and Medical Research Council
ID : GNT1198301
Informations de copyright
© 2024 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.
Références
Australian Government Department of Health. National Preventive Health Strategy 2021–2030. Canberra, ACT: Department of Health; 2021.
Guydish J, Passalacqua E, Pagano A, Martínez C, Le T, Chun J, et al. An international systematic review of smoking prevalence in addiction treatment. Addiction. 2016;111:220–230.
Conway KP, Green VR, Kasza KA, Silveira ML, Borek N, Kimmel HL, et al. Co‐occurrence of tobacco product use, substance use, and mental health problems among adults: findings from wave 1 (2013–2014) of the population assessment of tobacco and health (PATH) study. Drug Alcohol Depend. 2017;177:104–111.
Thurgood SL, McNeill A, Clark‐Carter D, Brose LS. A systematic review of smoking cessation interventions for adults in substance abuse treatment or recovery. Nicotine Tob Res. 2016;18:993–1001.
Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016;11:CD010274.
Royal Australian College of General Practitioners. Supporting smoking cessation: a guide for health professionals: chapter 2 pharmacotherapy for smoking cessation. Australia: RACGP; 2022. Available from: https://www.racgp.org.au/clinical‐resources/clinical‐guidelines/key‐racgp‐guidelines/view‐all‐racgp‐guidelines/supporting‐smoking‐cessation/pharmacotherapy‐for‐smoking‐cessation
Felicione NJ, Enlow P, Elswick D, Long D, Sullivan CR, Blank MD. A pilot investigation of the effect of electronic cigarettes on smoking behavior among opioid‐dependent smokers. Addict Behav. 2019;91:45–50.
Stein MD, Caviness C, Grimone K, Audet D, Anderson BJ, Bailey GL. An open trial of electronic cigarettes for smoking cessation among methadone‐maintained smokers. Nicotine Tob Res. 2016;18:1157–1162.
Baldassarri SR, Bernstein SL, Chupp GL, Slade MD, Fucito LM, Toll BA. Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: a pilot study. Addict Behav. 2018;80:1–5.
Bonevski B, Manning V, Wynne O, Gartner C, Borland R, Baker AL, et al. QuitNic: a pilot randomized controlled trial comparing nicotine vaping products with nicotine replacement therapy for smoking cessation following residential detoxification. Nicotine Tob Res. 2021;23:462–470.
Bonevski B, Rich J, Skelton E, Garfield J, Baker A, Segan C, et al. NEAT (NicotinE As Treatment) Trial: Protocol of a randomised controlled trial of vaporised nicotine products compared with nicotine replacement therapy following discharge from residential withdrawal services. medRxiv. 2022;2022: 05.15.22275118.
Banks E, Yazidjoglou A, Brown S, Nguyen M, Martin M, Beckwith K, et al. Electronic cigarettes and health outcomes: systematic review of global evidence report for the Australian Department of Health. ACT: Canberra; 2022.
Leavens ELS, Nollen NL, Ahluwalia JS, Mayo MS, Rice M, Brett EI, et al. Changes in dependence, withdrawal, and craving among adult smokers who switch to nicotine salt pod‐based e‐cigarettes. Addiction. 2022;117:207–215.
Therapeutic Goods Administration. Nicotine vaping product access. Canberra, ACT: Australian Department of Health; 2021 [updated 5/11/21]. Available from: https://www.tga.gov.au/node/935836
NSW Government. Quitting methods NSW: NSW Government. 2022. Available from: https://www.icanquit.com.au/quitting‐methods/nicotine‐replacement‐therapy‐(nrt)/benefits‐of‐nrt/how‐nrt‐works#:~:text=For%20example%2C%20a%20packet%2Da,like%20that%20of%20continued%20smoking
Meurk C, Ford P, Sharma R, Fitzgerald L, Gartner C. Views and preferences for nicotine products as an alternative to smoking: a focus group study of people living with mental disorders. Int J Environ Res Public Health. 2016;13:1166.
Wilson AJ, Bonevski B, Dunlop A, Shakeshaft A, Tzelepis F, Walsberger S, et al. ‘The lesser of two evils’: a qualitative study of staff and client experiences and beliefs about addressing tobacco in addiction treatment settings. Drug Alcohol Rev. 2016;35:92–101.
Lum A, Skelton E, Robinson M, Guillaumier A, Wynne O, Gartner C, et al. Barriers and facilitators to using vaporised nicotine products as smoking cessation aids among people receiving treatment for substance use disorder. Addict Behav. 2022;124:107097.
Van Heel M, Van Gucht D, Vanbrabant K, Baeyens F. The importance of conditioned stimuli in cigarette and e‐cigarette craving reduction by e‐cigarettes. Int J Environ Res Public Health. 2017;14:193.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32‐item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349–357.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.
Braun V, Clarke V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qual Res Psychol. 2021;18:328–352.
Terry G, Hayfield N, Clarke V, Braun V. Thematic analysis. The SAGE handbook of qualitative research in psychology [Internet]. Volume 2. Thousand Oaks, CA: SAGE; 2017. p. 17–37.
Fleiss J, Levin B, Paik M. The measurement of interrater agreement. In: Shewart W, Wilks S, Fleiss J, Levin B, Paik M, editors. Statistical Methods for Rates and Proportions. Hoboken, NJ: John Wiley & Sons, Inc; 2003. p. 598–626.
Li J, Hajek P, Pesola F, Wu Q, Phillips‐Waller A, Przulj D, et al. Cost‐effectiveness of e‐cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction. 2020;115:507–517.
Bonevski B, Bryant J, Paul C. Encouraging smoking cessation among disadvantaged groups: a qualitative study of the financial aspects of cessation. Drug Alcohol Rev. 2011;30:411–418.
Bonevski B, Bryant J, Lynagh M, Paul C. Money as motivation to quit: a survey of a non‐random Australian sample of socially disadvantaged smokers' views of the acceptability of cash incentives. Prev Med. 2012;55:122–126.
Cho A, Chan G, Gartner C. Motivations to change smoking behaviors between 2007 and 2019 in Australia: a repeated cross‐sectional study. Nicotine Tob Res. 2023;25:674–681.
Shoesmith E, Huddlestone L, Lorencatto F, Shahab L, Gilbody S, Ratschen E. Supporting smoking cessation and preventing relapse following a stay in a smoke‐free setting: a meta‐analysis and investigation of effective behaviour change techniques. Addiction. 2021;116:2978–2994.
Skelton E, Bonevski B, Tzelepis F, Shakeshaft A, Guillaumier A, Dunlop A, et al. Tobacco smoking policies in Australian alcohol and other drug treatment services, agreement between staff awareness and the written policy document. BMC Public Health. 2017;17:87.
Hartmann‐Boyce J, Lindson N, Butler AR, McRobbie H, Bullen C, Begh R, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2022;10:CD010216.
Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction. 2011;106:1176–1185.
Macaulay S, Grinzi P, Slota‐Kan S. Engaging patients who use alcohol and other drugs: a practical approach. Aust J Gen Pract. 2023;52:115–121.
Kollath‐Cattano C, Thrasher JF, Salloum RG, Albano AW, Jindal M, Durkin M, et al. Evaluation of a smoking cessation patient decision aid that integrates information about e‐cigarettes. Nicotine Tob Res. 2021;23:1880–1888.
Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self‐reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict. 1989;84:791–799.
Moolchan ET, Radzius A, Epstein DH, Uhl G, Gorelick DA, Cadet JL, et al. The Fagerstrom test for nicotine dependence and the diagnostic interview schedule: do they diagnose the same smokers? Addict Behav. 2002;27:101–113.
Lubman DI, Garfield JBB, Manning V, Berends L, Best D, Mugavin JM, et al. Characteristics of individuals presenting to treatment for primary alcohol problems versus other drug problems in the Australian patient pathways study. BMC Psychiatry. 2016;16:250.
Heaton J. “*Pseudonyms are used throughout”: a footnote, unpacked. Qual Inq. 2021;28:123–132.